参芪扶正注射液对慢支急性发作患者免疫功能的改善及疗效观察

摘要

Objective To investigate the curative effect of ShenqiFuzheng Injection on patients with acute at-tack of senile chronic bronchitis. Methods Eighty patients of senile chronic bronchitis in acute attack stage selected from Hainan Provincial Hospital of Traditional Chinese Medicine, Guangzhou Chinese Medicine University between Jan. 2014 and Sep. 2016 were randomly divided into treatment group and control group, with 40 cases in each group. The control group was given conventional treatment, and the treatment group was treated with ShenqiFuzheng Injection on the basis of conventional therapy. Treatment effects were compared between the two groups. Results After treat-ment, CD3+, CD4+and CD4+/CD8+were (1010±15.2)μL, (680±7.3)μL, (1.23±0.7) in the treatment group, significantly higher than those in the control group (P<0.05). CD8+was (960±10.7)μL in the treatment group, significantly lower than that in the control group (P<0.05). The PaCO2 level in the treatment group was (33.1±5.3) mmHg, significantly lower than that in the control group (P<0.05), and PaO2 level in the treatment group was (98.4±6.3) mmHg, significantly higher than that in the control group (P<0.05). After treatment, FVC, FEV1 and FEV1/FVC were (3.45 ± 0.2) L, (82.8 ± 9.6)％, (74.7 ± 8.5), significantly higher than those of the control group after treatment (P<0.05). The incidence of adverse reactions in the treatment group was only 0.75％, which is similar with that of the control group (P>0.05). Conclusion ShenqiFuzheng Injection on the basis of conventional therapy can ameliorate the immune function of patients with acute attack of senile chronic bronchitis, improve clinical curative effect, with low rate of adverse reaction, which is worthy of popularization and application.%目的 探讨参芪扶正注射液对慢性支气管炎急性发作患者免疫功能的影响,并观察其临床疗效.方法 选取2014年1月至2016年9月广州中医药大学附属海南省中医院急诊科门诊和住院部收治的80例慢性支气管炎急性发作患者作为观察对象,采用完全随机分组法分为观察组和对照组各40例.两组患者均给予抗感染和平喘祛痰治疗,观察组患者加用参芪扶正注射液.比较两组患者T淋巴细胞亚群的变化和临床疗效.结果 治疗后,观察组患者CD3+、CD4+及CD4+/CD8+比值分别为(1010±15.2)μL、(680±7.3)μL、(1.23±0.7),较对照组均有明显升高,CD8+为(960±10.7)μL,较对照组明显降低,差异均有统计学意义(P<0.05).治疗后,观察组患者PaCO2水平为(33.1±5.3)mmHg,较对照组明显较低,PaO2水平为(98.4±6.3)mmHg,较对照组明显较高,差异均有统计学意义(P<0.05).治疗后,观察组患者FVC、FEV1、FEV1/FVC指标分别为(3.45±0.2)L、(82.8±9.6)％、(74.7±8.5),高于对照组相关各项指标,差异均有统计学意义(P<0.05).治疗后,观察组不良反应发生率仅为0.75％,与对照组比较,差异无统计学意义(P>0.05).结论 慢性支气管炎急性发作期应用参芪扶正注射液联合治疗可以改善患者免疫功能,提高临床疗效,不良反应发生率低,值得推广应用.